Sign in: Staff/Students
A new risk-stratification tool which can accurately predict the likelihood of deterioration in adults hospitalised with COVID-19 has been developed by researchers from the UK Coronavirus Clinical Characterisation Consortium (known as ISARIC4C).
ISARIC4C is a consortium of NHS doctors and scientists from universities including the University of Liverpool, UCL, Imperial College London, the University of Edinburgh, and the University of Oxford.
Researchers say the online tool, made freely available to NHS doctors from today, could support clinicians’ decision making – helping to improve patient outcomes and ultimately save lives.
The tool assesses 11 measurements routinely collected from patients, including age, gender, and physical measurements (such as oxygen levels) along with some standard laboratory tests and calculates a percentage risk of deterioration, known as the ‘4C Deterioration Score’.
This innovation, due to be published in The Lancet Respiratory Medicine, builds on the Consortium’s previous work developing the ‘4C Mortality Score’ to predict the percentage risk of death from COVID-19 after admission to hospital. The ‘4C Mortality Score’ is already recommended for use by NHS England to guide anti-viral treatments (Remdesivir). Doctors will now see both the ‘4C Deterioration Score’ and the ‘4C Mortality Score’ at the same time, using the same tool.
The tool was developed using data from 74,944 individuals with COVID-19 admitted to 260 hospitals across England, Scotland and Wales, between February 6 and August 26, 2020.
Using a multivariable logistic regression model (where several measures are used to predict an outcome), researchers tested the 11 measures (age/gender/physical measures/lab tests) against the large patient cohort, to establish how, and to what to degree each of the measures affected the likelihood of deterioration.
Furthermore, researchers assessed how well the tool performed in nine NHS regions and found that it performed similarly well in each, suggesting that it is likely to be useful across the NHS. Importantly, the new risk score showed superior performance across the NHS, in comparison to previous risk scores.
The tool can potentially be incorporated into NHS Trusts’ Electronic Health Record System – used to manage all patient care – so that risk scores are automatically generated for patients.
Researchers suggest that the tool could also be used in other countries for risk-stratification, but should first be evaluated to test its accuracy in these settings.
ISARIC4C is principally funded by grants from the National Institute for Health Research (NIHR) and UK Medical Research Council.
Rishi K Gupta, Peter Openshaw, J Kenneth Baillie, Malcolm Semple, Mahdad Noursadeghi, on behalf of the ISARIC4C Investigators, Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study, Lancet Respiratory Medicine, DOI: 10.1016/S2213-2600(20)30559-2.
All recent news
Heseltine Institute report for LCR APPG leads calls for Westminster to deliver “clean, green and inclusive growth”
Using Liverpool’s e-scooters safely
Llama antibodies have “significant potential” as potent COVID-19 treatment
COVID-19 hospital mortality rates not reducing in patients with history of cancer, study finds
Follow us on social media
Liverpool is leading a new global network to bring together animal & human #coronavirus research communities.
Funded by @UKRI partners include @APHAgovuk @roslininstitute @Pirbright_Inst @Cambridge_Uni
#OneHealth #LivUniCovid @ThePandemicInst @livuniHLS https://bit.ly/3AEEqHr
Preventing the next global pandemics depends on the collective capacity of universities. For @Wonkhe this morning I’ve written about Liverpool, Covid-19 and @ThePandemicInst, and what next: https://wonkhe.com/blogs/if-pandemics-are-predictable-could-they-be-preventable/
Researchers from @livuniHLS have contributed to new research showing that llama antibodies have 'significant potential' as a #COVID19 treatment.
Published in @NatureComms today, the study was led by @RosFrankInst.
#LivUniCovid | @molvirol | @LivUni_IVES